LetterHidradenitis suppurativa markedly decreases quality of life and professional activity
References (21)
- et al.
Hidradenitis suppurativa: a comprehensive review
J Am Acad Dermatol
(2009) - et al.
Translating the science of quality of life into practice: what do dermatology life quality index scores mean?
J Invest Dermatol
(2005) - et al.
Quality of life impairment in hidradenitis suppurativa: a study of 61 cases
J Am Acad Dermatol
(2007) - et al.
Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients
J Am Acad Dermatol
(2007) - et al.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
Lancet
(2006) - et al.
Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures
J Am Acad Dermatol
(2000) - et al.
Clinical presentation
- et al.
Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use
Clin Exp Dermatol
(1994) - et al.
Morbidity in patients with hidradenitis suppurativa
Br J Dermatol
(2001)
There are more references available in the full text version of this article.
Cited by (199)
Taiwanese Dermatological Association (TDA) consensus recommendations for the definition, classification, diagnosis, and management of hidradenitis suppurativa
2024, Journal of the Formosan Medical AssociationAll-Cause and Cause-Specific Mortality Risks among Patients with Hidradenitis Suppurativa: A Korean Nationwide Population-Based Cohort Study
2023, Journal of Investigative DermatologyThe psychosocial burden of hidradenitis suppurativa in Singapore
2023, JAAD InternationalNeutrophil extracellular traps and neutrophilic dermatosis: an update review
2024, Cell Death Discovery
Funding sources: None.
Conflicts of interest: None declared.
Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.